Is Vorinostat on the market?

Vorinostat (Vorinostat) is the first histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of cutaneous T-cell lymphoma (CTCL), but it also failed to demonstrate efficacy in the treatment of acute myeloid leukemia in phase II studies. Vorinostat, or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for cutaneous T-cell lymphoma (CTCL), a type of skin cancer that may be used when the disease persists, worsens, or recurs during or after treatment with other drugs.

Vorinostat, the first of a new class of drugs called histone deacetylase inhibitors, also showed in a recent study that it had some activity against relapsed glioblastoma multiforme, resulting in a median overall survival of 5.7 months (versus 4-4.4 months in an earlier study). Further brain tumor trials are planned using vorinostat in combination with other drugs. Including vorinostat in the treatment of advanced non-small cell lung cancer showed improved response rates and increased median progression-free survival and overall survival. In a phase II trial, the drug achieved encouraging results in combination with idarubicin and cytarabine in the treatment of myelodysplastic syndrome.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.